BioMarin Pharmaceutical Inc. (BMRN) vs Madrigal Pharmaceuticals, Inc. (MDGL)
- BioMarin Pharmaceutical Inc. BMRN 54.68 −2.44%
- Madrigal Pharmaceuticals, Inc. MDGL 449.74 −2.19%
BioMarin Pharmaceutical Inc. and Madrigal Pharmaceuticals, Inc. are both Biotechnology companies. BioMarin Pharmaceutical Inc. and Madrigal Pharmaceuticals, Inc. are of similar size ($10.9B and $10.6B). Madrigal Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; BioMarin Pharmaceutical Inc. trades at 144×. Madrigal Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 149.0% against 11.2%. BioMarin Pharmaceutical Inc. has the higher net margin (2.14% vs −25.3%) and the higher return on invested capital (0.97% vs −787.3%). Across the 18 metrics below, BioMarin Pharmaceutical Inc. leads on 12 and Madrigal Pharmaceuticals, Inc. on 6.
Valuation
Profitability
| Metric | BMRN | MDGL | Biotechnology median |
|---|---|---|---|
| Gross margin | 76.12% | 91.48% | 65.16% |
| Operating margin | 4.38% | (25.13%) | 0.00% |
| Net margin | 2.14% | (25.32%) | 0.00% |
| Free cash flow margin | 21.28% | (16.07%) | 0.00% |
| Return on equity | 1.18% | (53.31%) | (56.36%) |
| Return on assets | 0.76% | (28.77%) | (48.04%) |
| Return on invested capital | 0.97% | (787.33%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack